XTLB Stock Overview
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
XTL Biopharmaceuticals Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.091 |
| 52 Week High | ₪0.17 |
| 52 Week Low | ₪0.03 |
| Beta | 1.03 |
| 1 Month Change | -21.55% |
| 3 Month Change | 184.38% |
| 1 Year Change | 111.63% |
| 3 Year Change | -26.02% |
| 5 Year Change | 8.33% |
| Change since IPO | -99.62% |
Recent News & Updates
Shareholder Returns
| XTLB | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | 1.1% | 3.2% | 2.9% |
| 1Y | 111.6% | 4.6% | 10.8% |
Return vs Industry: XTLB exceeded the IL Biotechs industry which returned 4.6% over the past year.
Return vs Market: XTLB exceeded the IL Market which returned 10.8% over the past year.
Price Volatility
| XTLB volatility | |
|---|---|
| XTLB Average Weekly Movement | 43.9% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 8.3% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: XTLB's share price has been volatile over the past 3 months.
Volatility Over Time: XTLB's weekly volatility has increased from 22% to 44% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | n/a | Shlomo Shalev | www.xtlbio.com |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.
XTL Biopharmaceuticals Ltd. Fundamentals Summary
| XTLB fundamental statistics | |
|---|---|
| Market cap | ₪49.59m |
| Earnings (TTM) | -₪8.53m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.8x
P/E RatioIs XTLB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XTLB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.25m |
| Earnings | -US$2.25m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0041 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XTLB perform over the long term?
See historical performance and comparison